Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

British Journal of Haematology

Volumn 170, Issue 3, 2015, Pages 398-407

  Giona, Fiorina ^a   Putti, Maria C ^b   Micalizzi, Concetta ^c   Menna, Giuseppe ^d   Moleti, Maria L ^a   Santoro, Nicola ^e   Iaria, Grazia ^f   Ladogana, Saverio ^g   Burnelli, Roberta ^h   Consarino, Caterina ⁱ   Varotto, Stefania ^b   Tucci, Francesca ^d   Messina, Chiara ^b   Nanni, Mauro ^a   Diverio, Daniela ^a   Biondi, Andrea ^j   Pession, Andrea ^k   Locatelli, Franco ^l,m   Piciocchi, Alfonso ⁿ   Gottardi, Enrico ^o   Saglio, Giuseppe ^o   Foà, Robin ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d Pausilipon Hospital   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h S ANNA HOSPITAL   (Italy)

ⁱ PUGLIESE CIACCIO HOSPITAL   (Italy)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l UNIVERSITY OF PAVIA   (Italy)

^m BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

ⁿ GIMEMA Data Center   (Italy)

^o UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

BCR ABL1; childhood; chronic myeloid leukaemia; imatinib; tyrosine kinase inhibitors

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEPATITIS; HUMAN; HYPOPLASIA; LONG TERM CARE; MALE; MEDULLARY HYPOPLASIA; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; ITALY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; ITALY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84942103657     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13453     Document Type: Article

References (39)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. & Hehlmann, R.; European LeukemiaNet. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809–1820.
2. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J. & Hehlmann, R.; European LeukemiaNet. (2009a) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 6041–6051.
3. Baccarani, M., Rosti, G., Castagnetti, F., Haznedaroglu, I., Porkka, K., Abruzzese, E., Alimena, G., Ehrencrona, H., Hjorth-Hansen, H., Kairisto, V., Levato, L., Martinelli, G., Nagler, A., Lanng Nielsen, J., Ozbek, U., Palandri, F., Palmieri, F., Pane, F., Rege-Cambrin, G., Russo, D., Specchia, G., Testoni, N., Weiss-Bjerrum, O., Saglio, G. & Simonsson, B. (2009b) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 113, 4497–4504.
4. Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Guilhot, F., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D.W., Larson, R.A., Lipton, J.H., Mahon, F.X., Martinelli, G., Mayer, J., Müller, M.C., Niederwieser, D., Pane, F., Radich, J.P., Rousselot, P., Saglio, G., Saußele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J.L., Goldman, J.M. & Hehlmann, R. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872–884.
5. Baccarani, M., Druker, B.J., Branford, S., Kim, D.W., Pane, F., Mongay, L., Mone, M., Ortmann, C.E., Kantarjian, H.M., Radich, J.P., Hughes, T.P., Cortes, J.E. & Guilhot, F. (2014) Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology, 99, 616–624.
6. Branford, S. & Hughes, T. (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. In: Myeloid Leukemia: Methods and Protocols: Methods in Molecular Medicine, Volume 125 (ed. by H. Iland, M. Hertzgerg & P. Marlton), pp. 93–106. Humana Press, Totowa, NJ.
7. Branford, S., Kim, D.W., Soverini, S., Haque, A., Shou, Y., Woodman, R.C., Kantarjian, H.M., Martinelli, G., Radich, J.P., Saglio, G., Hochhaus, A., Hughes, T.P. & Müller, M.C. (2012) Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. Journal of Clinical Oncology, 30, 4323–4329.
8. Branford, S., Yeung, D.T., Ross, D.M., Prime, J.A., Field, C.R., Altamura, H.K., Yeoman, A.L., Georgievski, J., Jamison, B.A., Phillis, S., Sullivan, B., Briggs, N.E., Hertzberg, M., Seymour, J.F., Reynolds, J. & Hughes, T.P. (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 121, 3818–3824.
9. Champagne, M.A., Capdeville, R., Krailo, M., Qu, W., Peng, B., Rosamilia, M., Therrien, M., Zoellner, U., Blaney, S.M. & Bernstein, M.; Children's Oncology Group phase 1 study. (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood, 104, 2655–2660.
10. Champagne, M.A., Fu, C.H., Chang, M., Chen, H., Gerbing, R.B., Alonzo, T.A., Cooley, L.D., Heerema, N.A., Oehler, V., Wood, C., French, M.E., Arceci, R.J., Smith, F.O. & Bernstein, M.L. (2011) Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 57, 56–62.
11. Cortes, J.E., Kantarjian, H.M., Goldberg, S.L., Powell, B.L., Giles, F.J., Wetzler, M., Akard, L., Burke, J.M., Kerr, R., Saleh, M., Salvado, A., McDougall, K., Albitar, M. & Radich, J.; Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group. (2009) High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Journal of Clinical Oncology, 27, 4754–4759.
12. Cortes, J.E., Baccarani, M., Guilhot, F., Druker, B.J., Branford, S., Kim, D.W., Pane, F., Pasquini, R., Goldberg, S.L., Kalaycio, M., Moiraghi, B., Rowe, J.M., Tothova, E., De Souza, C., Rudoltz, M., Yu, R., Krahnke, T., Kantarjian, H.M., Radich, J.P. & Hughes, T.P. (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology, 28, 424–430.
13. Cross, N.C., White, H.E., Müller, M.C., Saglio, G. & Hochhaus, A. (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 26, 2172–2175.
14. Cwynarski, K., Roberts, I.A., Iacobelli, S., van Biezen, A., Brand, R., Devergie, A., Vossen, J.M., Aljurf, M., Arcese, W., Locatelli, F., Dini, G., Niethammer, D., Niederwieser, D. & Apperley, J.F.; Paediatric and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation. (2003) Stem cell transplantation for chronic myeloid leukemia in children. Blood, 102, 1224–1231.
15. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031–1037.
16. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. & Larson, R.A.; IRIS Investigators. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 2408–2417.
17. de la Fuente, J., Baruchel, A., Biondi, A., de Bont, E., Dresse, M.F., Suttorp, M. & Millot, F.; International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee. (2014) Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. British Journal of Haematology, 167, 33–47.
18. Gabert, J., Beillard, E., van der Velden, V.H., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J.M., Cavé, H., Pane, F., Aerts, J.L., De Micheli, D., Thirion, X., Pradel, V., González, M., Viehmann, S., Malec, M., Saglio, G. & van Dongen, J.J. (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 17, 2318–2357.
19. Giona, F., Mariani, S., Gnessi, L., Moleti, M.L., Rea, M., De Vellis, A., Marzella, D., Testi, A.M. & Foà, R. (2013) Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica, 98, e25–e27.
20. Giona, F., Saglio, G., Moleti, M.L., Piciocchi, A., Rea, M., Nanni, M., Marzella, D., Testi, A.M., Mariani, S., Laurino, M., Diverio, D., Gottardi, E. & Foà, R. (2015) Long-term free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukemia. British Journal of Haematology, 168, 305–308.
21. Gugliotta, G., Castagnetti, F., Palandri, F., Breccia, M., Intermesoli, T., Capucci, A., Martino, B., Pregno, P., Rupoli, S., Ferrero, D., Gherlinzoni, F., Montefusco, E., Bocchia, M., Tiribelli, M., Pierri, I., Grifoni, F., Marzocchi, G., Amabile, M., Testoni, N., Martinelli, G., Alimena, G., Pane, F., Saglio, G., Baccarani, M. & Rosti, G.; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood, 117, 5591–5599.
22. Hanfstein, B., Müller, M.C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A., Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., Kolb, H.J., Krause, S.W., Hofmann, W.K., Schubert, J., Einsele, H., Dengler, J., Hänel, M., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Branford, S., Hughes, T.P., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Saußele, S. & Hochhaus, A.; SAKK & German CML Study Group. (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26, 2096–2102.
23. Hanfstein, B., Shlyakhto, V., Lauseker, M., Hehlmann, R., Saussele, S., Dietz, C., Erben, P., Fabarius, A., Proetel, U., Schnittger, S., Krause, S.W., Schubert, J., Einsele, H., Hänel, M., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C.F., Spiekermann, K., Baerlocher, G.M., Pfirrmann, M., Hasford, J., Hofmann, W.K., Hochhaus, A. & Müller, M.C.; SAKK & the German CML Study Group. (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia, 28, 1988–1992.
24. Hochhaus, A., O'Brien, S.G., Guilhot, F., Druker, B.J., Branford, S., Foroni, L., Goldman, J.M., Müller, M.C., Radich, J.P., Rudoltz, M., Mone, M., Gathmann, I., Hughes, T.P. & Larson, R.A.; IRIS Investigators. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23, 1054–1061.
25. Hughes, T.P., Branford, S., White, D.L., Reynolds, J., Koelmeyer, R., Seymour, J.F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M.F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A.K., Fay, K., Durrant, S., Januszewicz, H., Joske, D., Underhill, C., Dunkley, S., Lynch, K. & Grigg, A.; Australasian Leukaemia and Lymphoma Group. (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 112, 3965–3973.
26. Hughes, T.P., Hochhaus, A., Branford, S., Müller, M.C., Kaeda, J.S., Foroni, L., Druker, B.J., Guilhot, F., Larson, R.A., O’ Brien, S.G., Rudoltz, M.S., Mone, M., Wehrle, E., Modur, V., Goldman, J.M. & Radich, J.P.; IRIS investigators. (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116, 3758–3765.
27. Jabbour, E., Kantarjian, H., O'Brien, S., Shan, J., Quintas-Cardama, A., Faderl, S., Garcia-Manero, G., Ravandi, F., Rios, M.B. & Cortes, J. (2011) The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood, 118, 4541–4546.
28. Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M. & Hochhaus, A. (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 123, 494–500.
29. Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boqué, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M.B., Zhu, C., Szatrowski, T., Shapiro, D. & Baccarani, M. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362, 2260–2270.
30. Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P.; Intergroupe Français des Leucémies Myéloïdes Chroniques. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 11, 1029–1035.
31. Mariani, S., Giona, F., Basciani, S., Brama, M. & Gnessi, L. (2008) Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet, 372, 111–112.
32. Marin, D., Hedgley, C., Clark, R.E., Apperley, J., Foroni, L., Milojkovic, D., Pocock, C., Goldman, J.M. & O'Brien, S. (2012a) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood, 120, 291–294.
33. Marin, D., Ibrahim, A.R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R.M., Clark, R.E., Apperley, J.F., Milojkovic, D., Bua, M., Pavlu, J., Paliompeis, C., Reid, A., Rezvani, K., Goldman, J.M. & Foroni, L. (2012b) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Clinical Oncology, 30, 232–238.
34. Millot, F., Guilhot, J., Nelken, B., Leblanc, T., De Bont, E.S., Békassy, A.N., Gadner, H., Sufliarska, S., Stary, J., Gschaidmeier, H., Guilhot, F. & Suttorp, M. (2006) Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia, 20, 187–192.
35. Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., Mazingue, F., Lutz, P., Vérité, C., Berthou, C., Galambrun, C., Bernard, F., Yacouben, K., Bordigoni, P., Edan, C., Reguerre, Y., Couillault, G., Méchinaud, F., Cayuela, J.M. & Guilhot, F. (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. Journal of Clinical Oncology, 29, 2827–2832.
36. Millot, F., Guilhot, J., Baruchel, A., Petit, A., Bertrand, Y., Mazingue, F., Lutz, P., Vérité, C., Berthou, C., Galambrun, C., Sirvent, N., Yakouben, K., Schmitt, C., Gandemer, V., Reguerre, Y., Couillault, G., Mechinaud, F. & Cayuela, J.M. (2014) Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood, 124, 2408–2410.
37. Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., Paliompeis, C., Bua, M., Reid, A., Rezvani, K., O'Brien, S., Clark, R., Goldman, J. & Marin, D. (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood, 121, 2739–2742.
38. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Yeung, D.T., Dang, P., Goyne, J.M., Slader, C., Filshie, R.J., Mills, A.K., Melo, J.V., White, D.L., Grigg, A.P. & Hughes, T.P. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122, 515–522.
39. Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R.E., Hochhaus, A., Hughes, T.P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R.A. & Kantarjian, H.M.; ENESTnd Investigators. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362, 2251–2259.